Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients
INTRODUCTION: Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection.
AIM: To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density.
METHODS: Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger.
RESULTS: Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation.
CONCLUSIONS: Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension - 25(2018), 4 vom: 10. Dez., Seite 369-378 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Ciuceis, Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.02.2019 Date Revised 19.02.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40292-018-0279-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288405455 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288405455 | ||
| 003 | DE-627 | ||
| 005 | 20231225060227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40292-018-0279-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0961.xml |
| 035 | |a (DE-627)NLM288405455 | ||
| 035 | |a (NLM)30203268 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Ciuceis, Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.02.2019 | ||
| 500 | |a Date Revised 19.02.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection | ||
| 520 | |a AIM: To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density | ||
| 520 | |a METHODS: Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger | ||
| 520 | |a RESULTS: Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation | ||
| 520 | |a CONCLUSIONS: Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Capillaries | |
| 650 | 4 | |a Capillary density | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Endothelial progenitor cells | |
| 650 | 4 | |a Exenatide | |
| 650 | 4 | |a Incretin mimetics | |
| 650 | 4 | |a Liraglutide | |
| 650 | 4 | |a Microvascular density | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Incretins |2 NLM | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 650 | 7 | |a Exenatide |2 NLM | |
| 650 | 7 | |a 9P1872D4OL |2 NLM | |
| 700 | 1 | |a Agabiti-Rosei, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Rossini, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Caletti, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Coschignano, Maria Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari-Toninelli, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Ragni, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelli, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Cerudelli, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Airò, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Scarsi, Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Porteri, Enzo |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzoni, Damiano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension |d 1997 |g 25(2018), 4 vom: 10. Dez., Seite 369-378 |w (DE-627)NLM09364731X |x 1179-1985 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2018 |g number:4 |g day:10 |g month:12 |g pages:369-378 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40292-018-0279-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2018 |e 4 |b 10 |c 12 |h 369-378 | ||